Business Context and Reporting Period
This Form 8-K, dated December 6, 2023, is a current report filed by Neoleukin Therapeutics, Inc. (the "Company") to provide supplemental disclosures regarding its proposed merger with Neurogene Inc. The filing responds to three lawsuits and ten stockholder demands challenging the merger and alleging material misstatements in the previously filed proxy statement/prospectus. The Company states these disclosures are made solely to avoid litigation burdens and potential disruption to the merger, not as an admission of legal necessity.
Key Financial Metrics and Valuation
The filing does not report standard operating metrics such as revenue, profit, or cash flow for the current period, as both entities are pre-commercial biopharmaceutical companies. However, it provides specific valuation data and financial assumptions used in the merger analysis:
- Neurogene Estimated Net Cash: $42.0 million as of October 31, 2023.
- Neurogene Pre-Closing Financing Proceeds: Estimated at $95.0 million.
- Proposed Neurogene Valuation: $295.0 million (based on the Merger Agreement).
- Implied Equity Value Range (DCF Analysis): Leerink Partners calculated a range of approximately $445 million to $560 million, which is substantially higher than the proposed valuation.
- Implied Equity Value Range (Public Company Comparables): Adjusted equity value range of $173 million (25th percentile) to $419 million (75th percentile).
- Proposed Exchange Ratio: 1.7378x.
Material Changes and Supplemental Disclosures
The filing amends and restates several sections of the proxy statement/prospectus to address stockholder concerns:
- Transaction Committee Formation: Clarified that the Neoleukin board formed a Transaction Committee on December 17, 2022, appointing three disinterested directors to review strategic alternatives. The committee held six meetings during the due diligence period (June 6, 2023, to July 16, 2023) and was not dissolved thereafter.
- Valuation Methodology Updates:
- Discounted Cash Flow (DCF): Disclosed that the terminal value assumption involves a 10% annual decline in perpetuity, selected in consultation with management. The discount rate ranged from 10% to 12%.
- Public Company Comparables: Detailed the selection of seven "Selected Companies" focused on AAV-gene therapies. Leerink Partners applied a 20% illiquidity discount to the derived equity value range based on professional judgment.
- Executive Officer Arrangements: Disclosed that while no executive officers had negotiated post-merger arrangements as of the Merger Agreement date, Sean Smith and Donna Cochener subsequently entered negotiations for hourly transition consulting services. Ms. Cochener is also expected to provide consulting regarding legacy asset dispositions and lease reductions.
- Advisor Independence: Reiterated that Leerink Partners has not provided investment banking services to either company in the past two years, other than for this merger.
Guidance, Risks, and Contingencies
The filing contains extensive forward-looking statements and risk factors. Key contingencies and risks include:
- Legal Challenges: The merger is subject to ongoing litigation challenging the disclosures in the Registration Statement. The Company denies any violation of laws or duties.
- Transaction Conditions: Closing is contingent upon stockholder approval from both companies, satisfaction of regulatory conditions, and the absence of events that could terminate the Merger Agreement.
- Operational Risks: Both companies have limited operating histories and significant net losses. Risks include the ability to raise additional capital, advance product candidates through clinical trials, obtain regulatory approval, and commercialize products.
- Market and Listing Risks: Risks related to the combined company's ability to remain listed on the Nasdaq Capital Market under the ticker "NGNE" and uncertainties regarding the timing of the transaction.
Investor Verification Checklist
- Verify the status of the three pending lawsuits and ten stockholder demands challenging the merger.
- Review the full proxy statement/prospectus (Form S-4) to understand the complete valuation analysis and the context of the supplemental disclosures.
- Confirm the final terms of the consulting agreements with Sean Smith and Donna Cochener post-closing.
- Assess the validity of the 10% perpetual decline rate and the 20% illiquidity discount used in the valuation models.
- Monitor the progress of Neurogene's pre-closing financing to ensure the estimated $95.0 million proceeds are secured.